Brokerage Firms Say “Buy” This Stock
Cellebrite DI Ltd. (CLBT) stock is up 1.66% today and climbing. This stock has been given a “Buy” rating by a number of brokerage firms, making it worth a look for investors.
Eight different firms have said that this stock is a good buy right now. The average price over the last year for the stock has been $18.57, and it is currently priced at $17.13, which means it is slightly undervalued.
The expectation for this stock from at least some quarters is that it will climb, with many proposing a jump to $23.00 in the coming months. Several firms have issued a “buy” recommendation for Cellebrite DI stock when it hits $14-$15. One firm even said that the stock was overweight, which means that it is likely to outperform benchmark stocks and indices. In other words, even if the Nasdaq Composite only does fairly well, Cellebrite DI stock could do even better. It should not be held back by a sluggish market.
What to Know about Cellebrite DI
Over that last year, Cellebrite has experienced a low of $6.36 and a high of $17.82. The last time the company announced quarterly earnings was on August 15th, when they posted $0.10 earnings per share. That was above the analyst expectations of $0.08 per share. They brought in $95.7 million in that quarter alone, which was well above the predicted income of $91.94 million.
Revenue for the last quarter had increased by 24.8% compared to the same quarter last year. For this fiscal year, analysts estimate that the company will ring in $0.31 earnings per share.
This company- Cellebrite DI Ltd., provides investigative solutions for global clients. It serves customers in Europe, the United States, South America, Asia, the Middle East, and Africa. Their software solutions make it easy for companies to investigate reports of sexual assaults, security threats, human trafficking instances, and theft. Their products are useful for both companies and government agencies, and there is a growing market for the kind of software solutions that they provide.
According to multiple firms, Cellebrite DI could be ready to shoot up the stock market charts very quickly and surprise investors.